IL6 and acute graft versus host disease: Among the studied cytokines, IL-6 is already being considered as a potential biomarker for acute GVHD following allogenic HSCT, where elevated IL-6 levels were significantly associated with worsening outcomes, including severe CRS, acute GVHD, and reduced overall survival [33,34].